Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
Phase 2
Completed
- Conditions
- Psoriasis Vulgaris
- Interventions
- Drug: CT327 0.05%Drug: CT327 0.1%Drug: CT327 0.5%Drug: Placebo
- Registration Number
- NCT01465282
- Lead Sponsor
- Creabilis SA
- Brief Summary
The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
- Male and female subjects aged at least 18 years.
- Stable psoriasis vulgaris
Exclusion Criteria
- Subjects with guttate, erythrodermic, exfoliative or pustular psoriasis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 0.05% (w/w) CT327 ointment CT327 0.05% 0.05% (w/w) CT327 ointment applied BID for up to 8 weeks. 0.1% (w/w) CT327 ointment CT327 0.1% 0.1% (w/w) CT327 ointment applied BID for up to 8 weeks. 0.5% (w/w) CT327 ointment CT327 0.5% 0.5% (w/w) CT327 ointment applied BID for up to 8 weeks. Placebo ointment Placebo Placebo ointment
- Primary Outcome Measures
Name Time Method Efficacy of CT327 ointment (0.05%, 0.1% and 0.5% w/w) compared with placebo ointment. Week 8
- Secondary Outcome Measures
Name Time Method Local and systemic toleration 8 weeks